Are there any inhibitors in insulin pathway that can be used to treat Alzheimer's disease?
Best insight from top research papers
There are inhibitors in the insulin pathway that can be used to treat Alzheimer's disease. Studies have shown that drugs targeting brain insulin signaling, such as incretins, dipeptidyl peptidase IV inhibitors, thiazolidinediones, and metformin, have potential for the treatment of cognitive impairment and AD . Intranasal insulin administration has also been investigated as a method to improve brain insulin signaling and has shown promising results in animal studies and clinical trials . Additionally, small molecules acting as insulin/IGF signaling modulators have been developed and have shown potential for the treatment of neurodegenerative diseases, including Alzheimer's disease . These findings suggest that targeting the insulin pathway may be a viable approach for the treatment of Alzheimer's disease.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
4 Citations | The paper does not mention any inhibitors in the insulin pathway that can be used to treat Alzheimer's disease. The paper focuses on the relationship between Alzheimer's disease and insulin, proposing insulin replacement as a potential treatment approach. |
| Yes, the paper mentions that compounds acting as Insulin/IGF signaling modulators can be used as inhibitors in the treatment of neurodegenerative diseases, including Alzheimer's disease. | |
93 Citations | The paper does not mention any inhibitors in the insulin pathway that can be used to treat Alzheimer's disease. |
51 Citations | The paper mentions drugs that improve insulin sensitivity, including dipeptidyl peptidase IV inhibitors, which could potentially be used to treat Alzheimer's disease. |
| The paper does not mention any inhibitors in the insulin pathway that can be used to treat Alzheimer's disease. The paper discusses the potential use of insulin and insulin mimetics as therapeutic targets for Alzheimer's disease. |
Related Questions
What are the tau targeted therapies used in alzheimer disease?5 answersTau-targeted therapies for Alzheimer's disease (AD) focus on addressing the abnormal aggregation and accumulation of tau protein, a key hallmark of AD pathology. These therapies aim to modulate aberrant post-translational modifications (PTMs) of tau, inhibit tau aggregation, stabilize microtubules, and utilize immunotherapy and gene therapy approaches. Small molecules, peptides, and antibodies have shown promise in clinical trials for targeting tau pathology. Additionally, gene therapy has demonstrated reasonable success in targeting tau. The emphasis on tau-targeted therapies has increased due to the close relationship between tau pathology and cognitive decline in AD patients, surpassing the impact of amyloid plaques. These innovative approaches offer potential disease-modifying interventions that could significantly impact the treatment and management of AD in the future.
Which drugs are commonly used in the treatment of Alzheimer's disease?5 answersThe commonly used drugs in the treatment of Alzheimer's disease include cholinesterase inhibitors (ChEIs) such as donepezil, galantamine, and rivastigmine, as well as memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist. These drugs are approved for symptomatic therapies and aim to improve cognitive ability in patients with Alzheimer's disease. In addition to these pharmacological approaches, natural medicines, including traditional Chinese medicine, have shown promise in reducing oxidant stress, suppressing inflammation, and regulating gut microbiota homeostasis. However, the current treatments for Alzheimer's disease are primarily symptomatic and do not target the underlying disease process. Ongoing research is focused on developing disease-modifying therapies that target the pathological features of Alzheimer's disease, such as amyloid plaques and tau protein.
How does insulin resistance affect Alzheimer disease?5 answersInsulin resistance plays a significant role in the development and progression of Alzheimer's disease (AD). Studies have shown that insulin resistance in the brain, also known as brain insulin resistance (BIR), contributes to cognitive impairment in neurodegenerative diseases like AD. Insulin is involved in regulating glucose metabolism, neuronal energy production, and synaptic plasticity in the brain. BIR leads to impaired glucose uptake and utilization, decreased ATP production, and alterations in synaptic plasticity, ultimately affecting cognitive function. The connection between AD and type 2 diabetes mellitus (T2DM) has been extensively studied, and insulin resistance is considered a mechanism linking the two conditions. Furthermore, impaired BCAA metabolism, which is associated with insulin resistance, has been implicated in neurodegenerative diseases including AD. Targeting BIR and improving insulin sensitivity in the brain may offer potential therapeutic strategies for the treatment and prevention of AD.
What are the potential GSK3 inhibitors that are being studied for the treatment of Alzheimer's disease?4 answersSeveral potential GSK-3 inhibitors are being studied for the treatment of Alzheimer's disease. In one study, a series of analogues containing a pyrimidine-based hinge-binding heterocycle were synthesized and evaluated, leading to the identification of highly potent GSK-3 inhibitors with excellent kinase selectivity. Another study focused on the design and synthesis of novel chemicals containing maleimide and imidazole motif as dual inhibitors targeting GSK-3β. These compounds showed remarkable GSK-3β inhibitory activities. Additionally, a virtual screening approach was used to identify new and diverse GSK-3β allosteric inhibitors. Hits obtained from this study showed enhanced structural diversity and preliminary results as GSK-3β allosteric inhibitors. These potential GSK-3 inhibitors hold promise for the treatment of Alzheimer's disease by targeting the major pathways involved in the disease progression.
What treatments are there for Alzheimer’s?5 answersCurrent treatments for Alzheimer's disease include both non-pharmacological and pharmacological approaches. Non-pharmacological approaches focus on managing symptoms and behavioral problems. Pharmacological approaches include symptomatic therapies and disease-modifying therapies (DMTs). Symptomatic therapies aim to alleviate symptoms and include cholinesterase inhibitors (ChEIs) such as donepezil, galantamine, and rivastigmine, as well as memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist. DMTs are still under extensive research and aim to block the progression of the disease by targeting underlying mechanisms such as amyloid β plaques and neurofibrillary tangle formation. These therapies may include neuroprotective agents, anti-inflammatory agents, growth factor promotive agents, metabolic efficacious agents, stem cell therapies, and precision medicine approaches. In addition to FDA-approved therapies, traditional medicines and medicinal plants are being explored as potential treatments due to their lower side effects, easy access, and affordability.
What are the most promising new treatments for Alzheimer's disease?4 answersThe most promising new treatments for Alzheimer's disease include aducanumab, which is a human amyloid-β–directed monoclonal antibody that targets and clears amyloid-β plaques in the brain. Other potential disease-modifying therapies being studied include neuroprotective, anti-inflammatory, growth factor promotive, metabolic efficacious agents, and stem cell therapies. Additionally, intralipid treatment has been suggested as a potential treatment for Alzheimer's disease, although further clinical studies are needed to evaluate its effectiveness. These new treatments aim to interfere with the pathogenic steps responsible for the clinical symptoms of Alzheimer's disease, such as the deposition of amyloid β plaques and neurofibrillary tangle formation, inflammation, and neurotransmitter disturbance. Overall, these advancements in treatment offer hope for disease modification and improving the quality of life for individuals with Alzheimer's disease.